Participated · Series B · Jun 2026

INNOVAID’s Dentlink platform digitizes the end-to-end dental prosthetics workflow, integrating data acquisition, dentist-technician communication, fabrication, quality control, and logistics in a single system. The company says digitization has reduced prosthetic remake rates from around 10% to roughly 1%. Dentlink is live in six countries: the United States, Australia, Canada, New Zealand, Singapore, and the United Kingdom. INNOVAID reports that both clinic count and revenue have grown more than 2.5 times year over year and that its paid customer retention rate in the U.S. is 95%. The company has a strategic partnership with implant manufacturer Straumann to support global expansion. Using Series B proceeds, INNOVAID plans to scale operations in the U.S. and Australia and to build an automated, robot-integrated manufacturing center in Korea.

Participated · Series C · Mar 2026

MustBio develops next-generation immuno-oncology therapies using a multi-antibody platform called BICSTA and a tumor-selective immunocytokine platform called STARKINE. The company is advancing a portfolio of tri-specific fusion immuno-oncology candidates, with lead programs including MB5 (an IL-2–based therapeutic in clinical development) and MB7 (an IL-21–based program in R&D). Since its founding in 2021, MustBio has raised a total of 635억원 across prior rounds and the recent Series C. The firm has entered collaboration and licensing arrangements with Celltrion and was selected for JLABS Korea and the Seoul BioHub open innovation programs. Proceeds from the Series C are earmarked to accelerate MB5 clinical work, advance MB7 R&D, expand the pipeline, and support global business development and potential technology licensing. Management has stated plans to pursue additional tri-specific antibody R&D and broaden global partnerships.

Participated · Series B · Mar 2025

Seadronix develops AI-powered autonomous ship navigation and port-management systems, including NAVISS, Rec-SEA, and AVISS. Founded in 2015 and based in Seoul, South Korea, the company builds situational-awareness AI trained on extensive real-world operational data. Its technology has received global recognition, including a CES 2024 Innovation Award, the world's first type approval from a classification society, and certifications from the Ministry of Oceans and Fisheries. Seadronix participates in government-led programs such as the KRW 160 billion Autonomous Ship Technology Development Project and has secured international contracts in markets including Singapore and the Netherlands. The company plans to further advance ship AI and robotics technologies and accelerate global deployment of its autonomous navigation solutions. Management emphasizes delivering practical, revenue-generating AI solutions and leading efforts to set standards that comply with international autonomous navigation regulations. Seadronix develops AI software and monitoring systems to reduce sailor involvement in cargo-ship navigation. Founded in 2015, its two main products are a berthing monitoring system for docks and a separate monitoring system for open-water navigation, currently operating in four ports across Korea. The company says its proprietary systems could address about 75% of maritime accidents stemming from human error and environmental issues, including carbon dioxide leaks. Seadronix states its mission is to be an AI platform that ensures ocean safety and environmental protection. SoftBank Ventures Asia led a $5.8 million investment in the company, bringing total funding to date to $8.3 million. With the new funding, Seadronix plans to recruit more talent in AI, sensor fusion and navigation and to accelerate its global market penetration.

Participated · Seed · Jan 2023

XCENA designs the MX1, a prototype chip that brings compute into the memory module via CXL to process data inside DRAM modules and reduce expensive round trips between CPUs, GPUs, and memory. The company says the approach handles preprocessing, KV cache management, and data caching within memory, potentially shrinking infrastructure needs (claiming workloads that once required 10 servers could run on one). XCENA’s cores are built on RISC-V and the company emphasizes vertical integration, designing its own memory hierarchy, interconnect bus, and DRAM controller. The startup was founded in 2022 by Jin Kim, Dohun Kim, and Harry Juhyun Kim and has offices in Pangyo and Sunnyvale with over 90 staff. XCENA positions itself against rivals like Astera Labs and Marvell and plans mass production at Samsung foundries by the end of 2026 with revenue expected to begin in 2027; to date it has raised $185 million.

Participated · Equity · Mar 2021

Standigm develops workflow AI technology that spans novel target identification, lead generation, and drug repurposing through proprietary platforms such as Standigm ASK™, Standigm BEST™, Standigm Insight™ and the automated DarkMolFactory™. The company says it can generate first-in-class lead compounds within seven months and currently runs 22 in-house or collaborative drug pipelines. The recent $10 million investment will be used for clinical research of AI-driven drug compounds to strengthen Standigm’s competitiveness in the global market. Standigm has completed a series of investments from SK Chemicals and Pavilion Capital following a Pre-IPO funding round in March. NH Investment & Securities has been in charge of Standigm’s IPO process since March last year, indicating an ongoing push toward public markets. Founded in 2015 and headquartered in Seoul, Standigm is pursuing full-stack, AI-driven industrialization of drug discovery by automating molecular design and expanding automation across the discovery process. Standigm applies proprietary AI platforms to industrialize drug discovery, covering target identification, lead generation, repurposing, and automated molecular design. Its platforms include Standigm ASK™ for target discovery, Standigm BEST™ for lead selection, Standigm Insight™ for repurposing, and DarkMolFactory™ for automated molecular design. The company reports more than 20 preclinical pipelines and collaborations with over ten pharmaceutical or academic partners, including SK chemicals, Hanmi Pharmaceuticals, HK inno.N, and Samjin Pharmaceutical. Standigm and SK holdings C&C opened the iCLUE&ASK™ target-identification platform to the public in September. Management says proceeds from the recent financing will bolster B2B sales and support FDA investigational new drug (IND) filings and global collaborations. Standigm holds two patents for its AI technology granted in 2021 and has repurposed an FDA-approved drug for rheumatoid arthritis with a partner and filed for a patent.